Twist Bioscience (TWST) Other Accumulated Expenses (2018 - 2026)

Twist Bioscience has disclosed Other Accumulated Expenses across 9 years of filings, most recently posting $67.8 million for Q1 2026.

• In Q1 2026, Other Accumulated Expenses rose 841.68% year-over-year to $67.8 million; the TTM figure through Mar 2026 stood at $67.8 million (up 841.68% YoY), while the FY2025 annual figure was $35.2 million, up 505.16% from the prior year.
• Other Accumulated Expenses improved to $67.8 million in Q1 2026, from $13.5 million in the prior quarter.
• Over the last five years, Other Accumulated Expenses for TWST reached as high as $67.8 million in Q1 2026 and fell as low as $5.2 million in Q4 2024.
• The 5-year median for Other Accumulated Expenses is $10.0 million (2023), against an average of $15.5 million.
• Annual changes were most pronounced in 2023 — Other Accumulated Expenses plunged 60.47% — and 2026, when it surged 841.68%.
• A 5-year view of Other Accumulated Expenses shows it stood at $15.8 million in 2022, then sank by 59.44% to $6.4 million in 2023, then slipped by 18.32% to $5.2 million in 2024, then soared by 156.89% to $13.5 million in 2025, then soared by 403.85% to $67.8 million in 2026.
• According to Business Quant data, Other Accumulated Expenses over the past three periods registered $67.8 million, $13.5 million, and $35.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.